Anthem Biosciences Tells Delhi High Court It Won’t Launch Products Using Anti-Cancer Drug Alectinib

The Delhi High Court recorded Anthem Biosciences’ undertaking that it will not launch any products using the anti-cancer drug Alectinib until further orders.

The assurance came in Chugai Pharmaceutical’s patent infringement suit against the Bangalore-based company.

Justice Tejas Karia issued notice on Chugai’s application and noted Anthem’s commitment, aimed at preventing market disruption during litigation.

The case will continue to address issues of patent validity and infringement. The matter is listed for hearing on October 9.

[Chugai Seiyaku Kabushiki Kaisha & Anr. Vs Anthem Biosciences Limited]